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MaBACKGROUND High levels of apolipoprotein B (apoB) have been shown to predict atherosclerotic cardiovascular
disease (CVD) in adults even in the context of low levels of low-density lipoprotein cholesterol (LDL-C) or non–high-
density lipoprotein cholesterol (non–HDL-C).
OBJECTIVES This study aimed to quantify the associations between apoB and the discordance between apoB and
LDL-C or non–HDL-C in young adults and measured coronary artery calcium (CAC) in midlife.
METHODS Data were derived from a multicenter cohort study of young adults recruited at ages 18 to 30 years. All
participants with complete baseline CVD risk factor data, including apoB and year 25 (Y25) CAC score, were entered
into this study. Presence of CAC was deﬁned as having a positive, nonzero Agatston score as determined by
computed tomography. Baseline apoB values were divided into tertiles of 4 mutually exclusive concordant/discordant
groups, based on median apoB and LDL-C or non–HDL-C.
RESULTS Analysis included 2,794 participants (mean age: 25  3.6 years; body mass index: 24.5  5 kg/m2; and
44.4% male). Mean lipid values were as follows: total cholesterol: 177.3  33.1 mg/dl; LDL-C: 109.9  31.1 mg/dl;
non–HDL-C: 124.0  33.5 mg/dl; HDL-C: 53  12.8 mg/dl; and apoB: 90.7  24 mg/dl; median triglycerides were
61 mg/dl. Compared with the lowest apoB tertile, higher odds of developing Y25 CAC were seen in the middle (odds
ratio [OR]: 1.53) and high (OR: 2.28) tertiles based on traditional risk factor–adjusted models. High apoB and low
LDL-C or non–HDL-C discordance was also associated with Y25 CAC in adjusted models (OR: 1.55 and OR: 1.45,
respectively).
CONCLUSIONS These data suggest a dose–response association between apoB in young adults and the presence of
midlife CAC independent of baseline traditional CVD risk factors. (J Am Coll Cardiol 2016;67:193–201)
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ABBR EV I A T I ON S
AND ACRONYMS
apoB = apolipoprotein B
BMI = body mass index
BP = blood pressure
CAC = coronary artery calcium
CHD = coronary heart disease
CI = conﬁdence interval
CT = computed tomography
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
IDL = intermediate-density
lipoprotein
LDL-C = low-density
lipoprotein cholesterol
Lp(a) = lipoprotein (a)
non–HDL-C = non–high-
density lipoprotein cholesterol
OR = odds ratio
TC = total cholesterol
TG = triglyceride
Y25 = year 25
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194R etention of apolipoprotein B (apoB)–containing particles within thearterial wall is fundamental to the
pathogenesis of atherosclerotic disease. The
rate and extent to which this retention occurs
is a function of the concentration of apoB-
containing particles in blood, the permeability
of the vascular endothelium, and the binding
afﬁnity of the apoB particles to the collagen
and elastin of the arterial wall (1,2).SEE PAGE 202Three different measures of atherogenic
risk associated with apoB particles have
been proposed: low-density lipoprotein
cholesterol (LDL-C), non–high-density lipo-
protein cholesterol (non–HDL-C), and apoB.
LDL-C represents the total concentration of
cholesterol within LDL, intermediate-density
lipoprotein (IDL) cholesterol, and lipoprotein
(a) [Lp(a)] particles, whereas non–HDL-C is the
total concentration of cholesterol within LDL,
IDL, Lp(a), and very low-density lipoprotein
particles. However, apoB represents thenumber of LDL, IDL, Lp(a), and very low-density lipo-
protein particles because each lipoprotein particle
contains 1molecule of apoB (2). Elevated levels of LDL-
C and non–HDL-C in early adulthood are associated
with coronary artery calciﬁcation, awell-validated and
potent marker of risk for nonfatal and fatal myocardial
infarction in middle age (3). However, the association
between levels of apoB in early adulthood and coro-
nary artery calcium (CAC) in midlife has not yet been
quantiﬁed.
Statistical attempts to compare the predictive
values of apoB, non–HDL-C, and LDL-C for clinical CVD
events in middle-aged adults using receiver-operating
characteristic curves and net reclassiﬁcation im-
provement have not demonstrated clear evidence of
predictive superiority of onemeasure over another (4).
However, in these analyses, the measures have been
compared simultaneously as independent markers
when, in fact, they are tightly linked biologically,
possibly reducing the validity of the c-statistic (5).
Nevertheless, the mass of cholesterol within apoB
particles varies substantially in approximately 10% to
20% of individuals; their apoB particles are either
enriched in cholesterol or alternatively depleted in
cholesterol (Central Illustration) (6). When the apoB
particles contain an average amount of cholesterol,
the markers are concordant; therefore, LDL-C, non–
HDL-C, and apoB predict risk equally well. Only when
the apoB particles contain more or less than the
average concentration of cholesterol, resulting ineither lipid-rich or lipid-deplete apoB particles, are
these markers discordant, and only under these
circumstances, can their predictive powers differ.
Discordance analysis is an analytical technique in
which biologically linked variables are analyzed
by groups of concordance or discordance between their
relative distributions. The advantage of discordance
analysis over conventional approaches is that differ-
ences in predictive powers in the discordant groups will
not be attenuated by correlation between themarkers of
risk in concordant groups (7). Accordingly, the objective
of this study is to use discordance analysis to evaluate
the associations of apoB with LDL-C and non–HDL-C in
early adulthood and their joint or discordant effects on
long-term risk of developing coronary calciﬁcation by
middle age.
METHODS
STUDY POPULATION AND RISK FACTOR
MEASUREMENT. The CARDIA (Coronary Artery Risk
Development in Young Adults) study is a multicenter,
longitudinal, population-based cohort of 5,115 black
and white men and women, who were ages 18 to 30
years at year 0 (1985 to 1986) and who were recruited
from 4 urban areas (Birmingham, Alabama; Chicago,
Illinois; Minneapolis, Minnesota; and Oakland, Cali-
fornia). Within each center, the sample was designed
to have approximately equal numbers of participants
by sex, race (black or white), age (18 to 24 years or 25 to
30 years), and education (high school graduate or less,
or beyond high school). Seven follow-up examinations
have been conducted at years 2, 5, 7, 10, 15, 20, and
25 (2010 to 2011), with 72% of the surviving cohort
attending the year 25 (Y25) examination (8,9). All ex-
aminations were approved by the institutional review
boards at each participating institution, and all par-
ticipants gave written informed consent.
Our study population included 3,036 women
(nonpregnant) and men in CARDIA with measure-
ments for apoB at baseline who also underwent CAC
measurement at Y25. We excluded participants with
CVD at baseline (n ¼ 181), those with missing lipid
data at baseline or Y25 (n ¼ 35), and persons with
missing key covariates of interest (n ¼ 25) at baseline
and Y25. Based on concerns of confounding due to
exogenous hormone administration, we excluded 1
participant who underwent a sex change at year 15.
The ﬁnal cohort for analysis included 2,794 partici-
pants (535 black men, 803 black women, 682 white
men, and 774 white women). The 242 participants
who were excluded were on average 1 year older than
included participants, but there were no other sig-
niﬁcant differences in covariates.
CENTRAL ILLUSTRATION Apo B, LDL-C Discordance in Young Adults Is Associated With Coronary Artery Calciﬁcation
in Mid-Life: The Biologic Basis for Discordance Analysis
Concordant
Lowest Risk
Discordant
  Low Risk
Discordant
 High Risk
 Concordant
Highest Risk
  Low apoB/Low
          LDL-C
(Low Non-HDL-C)
      Low apoB/
      High LDL-C
(High Non-HDL-C)
      High apoB/
      Low LDL-C
(Low Non-HDL-C)
      High apoB/
      High LDL-C
(High Non-HDL-C)
Wilkins, J.T. et al. J Am Coll Cardiol. 2016; 67(2):193–201.
When apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) (or non–high-density lipoprotein cholesterol [non–HDL-C]) are concor-
dant within an individual (columns 1 and 4), apoB particles contain an average amount of cholesterol. When concordant, apoB, LDL-C, and non–HDL-C
predict risk similarly well. When apoB and LDL-C (or non–HDL-C) are discordant, the particles are either cholesterol-enriched (column 2), or cholesterol-
deplete (column 3). In discordant groups, the risk for subclinical atherosclerosis appears more strongly associated with apoB than with LDL-C or non–
HDL-C.
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195Information on age, sex, race, and smoking status
was collected by questionnaire. Smoking was deﬁned
as at least 5 cigarettes per week almost every week for
at least 3 months. Interviewers at baseline ascer-
tained medical history. Body mass index (BMI) was
calculated as the weight in kilograms divided by the
square of height in meters. Obesity was deﬁned as a
BMI $30 kg/m2. Physical activity was assessed using a
standard instrument; energy expenditure for moder-
ate and vigorous activities was calculated in exercise
units (8).
Baseline blood pressure (BP) was measured 3 times
by random zero sphygmomanometer, and the mean
of the second and third measurements was used; BP
at Y25 used an Omron HEM907XL oscillometer
(Omron Corp., Schaumburg, Illinois) calibrated to the
random-zero readings. Hypertension was deﬁned as
systolic BP $140 mm Hg, diastolic BP $90 mm Hg, or
taking antihypertensive medication. Diabetes wasdeﬁned as fasting glucose $126 mg/dl or taking anti-
diabetic medication.
Total cholesterol (TC) and HDL-C were measured
using serum from a fasting blood draw that was
separated into plasma frozen at 70C before analysis
in a central laboratory. LDL-C concentration was
estimated using the Friedewald equation. Non–HDL-
C was calculated as TC minus HDL-C. ApoB was
measured by enzyme-linked immunosorbent assay.
Methods for CACmeasurement have been published
previously (10). Brieﬂy, at Y25, CAC was measured
when participants were aged 43 to 55 years by
computed tomography (CT) of the chest with electron
beam CT (Imatron C-150, GE Imatron, San Francisco,
California) or multidetector CT scanners (Lightspeed,
GE Healthcare, Buckinghamshire, United Kingdom, or
Volume Zoom CT, Siemens Corporation, Munich, Ger-
many). One set of images was obtained containing 40
to 45 sequential 3-mm transverse images from the
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196aortic root to the cardiac apex in 2 gated scans, which
were transmitted electronically to the CARDIA CT
Reading Center, where an expert investigator
reviewed and adjudicated all discordant scan pairs.
A total CAC score was computed by summing the
Agatston score for each coronary artery and across all
coronary arteries. The presence of CAC was deﬁned by
a total Agatston score >0 (11).
STATISTICAL ANALYSES. The medians and tertiles
for apoB, LDL-C, and non–HDL-C at baseline were
computed ﬁrst, with correlations assessed using
Spearman rank correlation and examined graphically
using scatterplots. Participants were then classiﬁed
into apoB, LDL-C, and non–HDL-C groups based on
tertiles of each measure within the entire cohort.
In addition, 4 mutually exclusive concordance/
discordance categories were deﬁned based on the
medians of apoB and LDL-C or non–HDL-C concentra-
tion levels: low/low (less than the medians of both
apoB and LDL-C or non–HDL-C), low/high (less than
the median of apoB and greater than or equal to the
median of LDL-C of non–HDL-C), high/low (greater
than or equal to the median of apoB and less than the
median LDL-C or non–HDL-C), and high/high (greater
than or equal to themedians of both apoB and LDL-C or
non–HDL-C). Discordance was deﬁned as apoB greater
than or equal to themedianwith the othermeasure less
than the median or vice versa. We chose median cut-
points over percentile differences in the distribution of
apoB, LDL-C, or non–HDL-C to maximize each group’s
size so that we could generate stable measures of as-
sociation among discordance groups and midlife CAC.
Baseline characteristics were compared across the
tertiles of apoB and across the 4 concordance/
discordance groups with signiﬁcance tests by the
chi-square test for categorical variables or analysis of
variance (or Kruskal-Wallis when appropriate) for
continuous variables. We also examined the Y25
characteristics across the 4 concordance/discordance
groups for each set of apoB and LDL-C or non–HDL-C
combinations separately.
Logistic regression analyses were used to examine
the odds ratios (ORs) and 95% conﬁdence intervals
(CIs) of having CAC >0 at Y25 among tertiles of apoB,
LDL-C, and non–HDL-C separately, with the lowest
tertile as the referent, in 3 models: model 1 (adjusted
for age, sex, and race), model 2 (all variables in model
1 plus smoking status, systolic BP, antihypertensive
medication use, diabetes, and BMI), and model 3
(all variables in model 2 plus HDL-C and lipid-
lowering medication use). Standard techniques were
used to select models and to test for model validity
(e.g., goodness of ﬁt, interactions, and collinearity)
(12). Adjusting for the same sets of covariates,multivariable logistic regression analyses were used
to model the odds of having CAC at the 25-year
follow-up for each set of concordance/discordance
groups in separate models, with the low/low group
as the referent. The Wald chi-square test was used
to test for statistical signiﬁcance of the differences
between the referent and other categories within a
group. To conﬁrm the robustness of our results,
we conducted sensitivity analyses using relative risk
regression (generalized linear Poisson model with
robust error variance) to estimate the risk ratios
and 95% CIs of having CAC >0 at Y25, adjusting for
the same set of covariates. All analyses were con-
ducted using SAS statistical software version 9.4
(SAS Institute Inc., Cary, North Carolina). A 2-tailed
p value <0.05 was considered statistically signiﬁcant.
RESULTS
At baseline, the sample was 44.4% male and 47.6%
African American, with a mean age of 25  3.6 years
and a mean BMI of 24.5 kg/m2. Of the participants,
27% were current smokers, and 11.4% were obese at
the baseline examination (year 0). The mean TC was
177 mg/dl, HDL-C 53 mg/dl, LDL-C 110 mg/dl, and
non–HDL-C 124 mg/dl; the median triglyceride (TG)
concentration was 61 mg/dl (interquartile range: 46
to 83). The mean apoB was 91 mg/dl.
According to the baseline characteristics of the
participants stratiﬁed by tertiles of apoB concentra-
tion (Table 1), mean age differed slightly across the
groups (range: 24 to 25 years). There were slightly
more men in the middle and high apoB tertiles than
the low apoB tertile. The proportion of African
Americans did not vary among the tertiles of apoB.
Participants with higher apoB tertiles had modestly
higher waist circumference, BMI, and prevalent
obesity than the lowest tertile. There were small
differences in systolic BP and blood glucose levels,
which were statistically, but not clinically, signiﬁ-
cant. The expected direct associations among apoB,
TC, LDL-C, and non–HDL-C were present. Of inter-
est, there was a clear inverse association between
HDL-C and apoB, and there was a direct relation
between plasma TGs and apoB. Nevertheless, the
median values for TGs and the interquartile range
(25th to 75th percentile values) were within the
normal range.
The baseline and 25-year follow-up characteristics
of participants are shown in Tables 2 and 3, strati-
ﬁed by the 4 apoB/LDL-C concordance/discordance
groups at the respective examination (apoB mea-
surements are not available at Y25). Approximately
9% of participants were in each of the low apoB/
TABLE 1 Baseline Characteristics by Apolipoprotein B Tertiles*
Low
(n ¼ 915)
Middle
(n ¼ 944)
High
(n ¼ 935) p Value†
Age, yrs 24.5  3.8 25.1  3.5 25.4  3.6 <0.001
Male 40.3 44.1 46.2 0.036
African American 47.0 47.3 49.3 0.562
Education, less than HS graduation 6.9 7.9 8.5 0.440
Waist circumference, cm 75.0  10.1 77.1  10.2 80.7  12.0 <0.001
BMI, kg/m2 23.5  4.5 24.4  4.6 25.6  5.3 <0.001
Obese, BMI >30 kg/m2 7.0 9.2 17.1 <0.001
Current smoking 27.8 24.8 28.9 0.120
Physical activity, exercise unit 378.0 (203.0–588.0) 357.0 (208.0–574.0) 340.0 (173.0–567.0) 0.037
Systolic BP, mm Hg 108.8  10.4 110.0  10.1 110.8  11.1 <0.001
Diastolic BP, mm Hg 67.6  9.3 68.4  9.4 68.9  9.5 0.010
Hypertension 1.5 2.2 2.8 0.183
Fasting glucose, mg/100 ml 81.1  8.4 81.6  11.0 82.8  9.4 0.001
Diabetes‡ 0.2 0.3 0.6 0.313
Lipid-lowering medication 0.0 0.1 0.1 0.614
Lipids, mg/dl
LDL-C 82.5  18.3 108.4  17.3 138.1  26.0 <0.001
NHDL-C 93.6  19.1 121.8  18.0 156.0  27.0 <0.001
HDL-C 56.1  12.7 53.7  12.7 49.6  11.8 <0.001
Triglycerides 50.0 (39.0–67.0) 59.0 (46.0–77.0) 76.0 (58.0–104.0) <0.001
ApoB 66.4  9.7 87.9  5.7 117.0  16.7 <0.001
Total cholesterol 150.0  21.5 175.5  20.7 205.5  28.3 <0.001
Values are mean  SD, %, or median (interquartile range). *Tertile ranges are low (22 to 78 mg/dl), middle (79 to 98 mg/dl), and high (99 to 292 mg/dl). †p value for test of
difference across tertiles of apolipoprotein B (apoB) using the chi-square test (categorical variables) or analysis of variance (continuous variables) or Kruskal-Wallis test
(nonparametric comparisons). ‡Deﬁned as fasting glucose $126 mg/dl or use of antidiabetic medication.
BMI ¼ body mass index; BP ¼ blood pressure; HDL-C ¼ high-density lipoprotein cholesterol; HS ¼ high school; LDL-C ¼ low-density lipoprotein cholesterol; NHDL-C ¼ non–
HDL-C (deﬁned as total cholesterol minus HDL-C).
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197high LDL-C (the group with cholesterol-enriched
particles) and the high apoB/low LDL-C (the group
with cholesterol-depleted particles) discordant
groups. At baseline, there were small but statisti-
cally signiﬁcant differences in waist circumference,
BMI, and percent obese across concordance/discordance
groups, with the values being higher in the higher apoB
groups.
At Y25 (Table 3), it is notable that although BMI and
prevalence of obesity were certainly higher than at
baseline, there were no systematic trends across
groups noted for these measures. Similarly, there
were no signiﬁcant differences in BP or hypertension
prevalence across the 4 groups. In contrast, blood
glucose and the proportion of participants with dia-
betes were higher in both high apoB groups. Plasma
TGs were higher in both high apoB groups although
the average remained within the normal range.
The baseline and Y25 characteristics for the apoB/
non–HDL-C concordance/discordance groups are
shown in Online Tables 1 and 2, respectively. Each of
the apoB/non–HDL-C discordant groups contains
approximately 9% of participants. The overall pattern
of results are similar to those observed in the apoB/
LDL-C analyses.The ORs and 95% CIs of having CAC >0 at Y25 were
calculated separately for the apoB, LDL-C, and non–
HDL-C tertiles (Table 4). Using the lowest tertile as
the referent, the middle (OR: 1.53; 95% CI: 1.20 to
1.94) and high (OR: 2.28; 95% CI: 1.79 to 2.89) baseline
apoB tertiles had signiﬁcantly greater odds for CAC at
Y25 in the multivariable-adjusted models. Similar
overall results were observed across tertiles of LDL-C
and non–HDL-C.
Table 4 also displays the ORs of CAC score of >0 at
Y25 for the 4 concordance/discordance categories of
each set of apoB and LDL-C or non–HDL-C groups
separately. The low/low phenotypes constituted the
reference group for both LDL-C and non–HDL-C
analyses. The ORs of the low apoB/high LDL-C and the
low apoB/high non–HDL-C groups were signiﬁcantly
higher than baseline only in the unadjusted compari-
sons and were not statistically signiﬁcantly different in
the adjusted models. Thus, when either LDL-C or non–
HDL-C was high, but apoB was low, the odds of coro-
nary artery calciﬁcation were not higher than the
referent and were lower than the 2 groups with high
apoB. In contrast, the ORs for the high apoB/low LDL-C
and the high apoB/low non–HDL-C groups were
signiﬁcantly higher than the referent in both the
TABLE 2 Baseline Characteristics of Participants by Concordance/Discordance Groups
Concordance/Discordance Groups
p Value*
Low/Low
(n ¼ 1,153, 41.3%)
Low/High
(n ¼ 244, 8.7%)
High/Low
(n ¼ 241, 8.6%)
High/High
(n ¼ 1,156, 41.4%)
Age, yrs 24.6  3.7 25.5  3.5 25.1  3.5 25.3  3.6 <0.001
Male 42.0 41.0 38.2 46.8 0.022
African American 45.5 52.9 47.7 49.3 0.106
Education, less than HS graduation 7.7 4.5 8.7 8.3 0.222
Waist circumference, cm 75.2  9.9 77.5  10.9 77.6  11.5 80.1  11.6 <0.001
BMI, kg/m2 23.5  4.4 25.0  5.1 24.6  5.2 25.4  5.1 <0.001
Obese, BMI >30 kg/m2 7.1 11.9 10.8 15.1 <0.001
Current smoking 27.4 18.9 32.4 27.5 0.008
Physical activity, exercise unit† 379.0 (212.0–597.0) 353.0 (172.0–549.0) 378.0 (192.0–558.0) 331.5 (183.5–552.0) 0.004
Systolic BP, mm Hg 108.9  10.2 109.5  10.5 110.7  11.2 110.6  10.8 0.001
Diastolic BP, mm Hg 67.4  9.1 68.7  9.5 68.4  10.2 69.1  9.4 <0.001
Hypertension 1.3 2.1 3.7 2.8 0.032
Fasting glucose, mg/100 ml 81.2  8.9 81.4  8.7 81.8  8.9 82.6  10.8 0.004
Diabetes 0.2 0.4 0.4 0.6 0.431
Lipid-lowering medication 0.0 0.0 0.0 0.2 0.418
Lipids, mg/dl
LDL-C‡ 83.4  15.2 119.0  12.5 96.1  8.5 137.2  22.7 <0.001
NHDL-C 95.0  16.1 130.7  14.2 113.7  12.6 153.6  24.9 <0.001
HDL-C 55.7  12.7 54.5  11.9 51.6  13.7 50.6  12.1 <0.001
Triglycerides 52.0 (40.0–68.0) 52.0 (41.5–69.5) 70.0 (52.0–101.0) 71.0 (54.0–96.0) <0.001
ApoB§ 70.5  11.2 79.9  7.9 99.3  18.1 110.9  17.1 <0.001
Total cholesterol 150.7  18.6 185.2  17.7 165.3  15.5 204.3  25.9 <0.001
Values are mean  SD, %, or median (interquartile range). *Overall p values for comparison across groups using analysis of variance for continuous variables, or chi-square test
for categorical variables, or Kruskal-Wallis test for nonparametric variables. †Physical activity was assessed using a standard instrument; energy expenditure for moderate and
vigorous activities was calculated in exercise units. ‡Median: 107.0 mg/dl. §Median: 88.9 mg/dl.
Abbreviations as in Table 1.
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198unadjusted and adjusted models. Thus, when either
LDL-C or non–HDL-C were low, but apoB was high,
the odds of developing coronary artery calciﬁcation
were signiﬁcantly higher than in the 2 groups with low
apoB. We obtained similar results in the sensitivity
analyses using estimated risk ratios instead of the odds
of having CAC >0 at Y25 (data not shown).
Finally, odds of CAC >0 at Y25 were highest for the
high apoB/high LDL-C and high apoB/high non–HDL-
C strata—those with greatest numbers of apoB parti-
cles. In this group, apoB particles contained an
average mass of cholesterol.
DISCUSSION
This study demonstrates a strong association be-
tween plasma levels of apoB in young adulthood
(mean: 25 years) and coronary calciﬁcation in middle
age (mean: 50 years) (Central Illustration). In discor-
dant groups, the odds for CAC in midlife were
signiﬁcantly and consistently higher when apoB was
greater than the median and not signiﬁcantly higher
than the referent when apoB was below the median,
suggesting that the risk for CAC is more stronglyinﬂuenced by apoB than by LDL-C and non–HDL-C in
early adulthood. Therefore, this discordance analysis
suggests that the measurement of apoB at age
25 years may identify subgroups (18% of sample) in
which apoB levels may predict midlife coronary
calciﬁcation better than LDL-C and non–HDL-C.
In this analysis and multiple previous studies that
used discordance analysis, atherosclerotic CVD risk is
associated with absolute apoB concentrations more
than LDL-C and non–HDL-C. Of note, the group with
the high LDL-C or non–HDL-C and high apoB had the
highest risks for CAC in midlife (Table 4). This group
had the highest apoB (110.9 mg/dl) and cholesterol
concentrations; thus, particles were numerous but of
average cholesterol concentration (Table 2). Because
an increased risk for CAC was only seen in partici-
pants with apoB greater than the median, these re-
sults suggest that the increased risks for CAC may be
explained by the substantial differences in apoB
among the groups. Likewise, in the discordant group
with low apoB and high LDL-C, there was a trend
toward high CAC risk; this trend may be explained by
the 9 mg/dl higher mean apoB in this discordance
group compared with the referent (Tables 2 and 4).
TABLE 3 Year 25 Characteristics of Participants by Concordance/Discordance Groups
Concordance/Discordance Groups
p Value*
Low/Low
(n ¼ 1,153, 41.3%)
Low/High
(n ¼ 244, 8.7%)
High/Low
(n ¼ 241, 8.6%)
High/High
(n ¼ 1.156, 41.4%)
Waist circumference, cm 92.3  15.7 95.8  16.6 93.3  16.8 96.9  15.7 <0.001
BMI, kg/m2 29.4  7.2 31.6  8.3 30.0  6.9 31.0  7.1 <0.001
Obese, BMI >30 kg/m2 38.9 47.3 43.6 48.4 <0.001
Current smoking 18.5 12.8 21.0 16.1 0.047
Physical activity, exercise unit 283.0 (142.0–496.0) 250.0 (108.0–471.0) 254.0 (118.0–474.0) 276.0 (116.0–486.0) 0.277
Systolic BP, mm Hg 119.0  16.1 120.6  16.9 118.7  13.9 120.0  15.5 0.270
Diastolic BP, mm Hg 74.5  11.6 75.5  11.1 74.6  10.0 75.3  10.8 0.278
Hypertension 14.3 14.8 10.8 14.4 0.498
Fasting glucose, mg/100 ml 96.0  20.4 96.1  20.8 101.9  30.7 102.3  34.2 <0.001
Diabetes 9.0 7.8 13.8 14.5 <0.001
Lipid-lowering medication 4.3 13.5 12.5 24.3 <0.001
Lipids, mg/dl
LDL-C 99.6  27.1 115.5  28.1 107.3  26.6 124.5  35.0 <0.001
NHDL-C 120.0  31.5 134.7  31.1 130.0  31.0 148.2  37.9 <0.001
HDL-C 60.3  19.0 59.1  16.9 57.6  19.0 55.4  16.6 <0.001
Triglycerides 87.0 (62.0–122.0) 82.5 (63.0–114.5) 97.0 (73.0–134.0) 104.0 (75.0–145.5) <0.001
Total cholesterol 180.4  31.5 193.8  33.8 187.6  32.5 203.6  38.5 <0.001
CAC
0 931 (80.7) 183 (75.0) 169 (70.1) 726 (62.8) <0.001
>0, Agatston unit 25.7 (6.2–76.6) 44.0 (16.4–157.7) 51.6 (19.4–124.3) 61.6 (14.9–218.8) <0.001
Values are mean  SD, %, median (interquartile range), or n (%). *Overall p values for comparison across groups using analysis of variance for continuous variables, or chi-square test for
categorical variables, or Kruskal-Wallis test for nonparametric variables.
CAC ¼ coronary artery calcium; other abbreviations as in Table 1.
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199Obesity and dysglycemia are widely regarded to be
major CVD risk factors that produce elevated levels of
cholesterol-depleted apoB particles. In this sample,
differences in plasma TGs, BMI, dysglycemia, and BP
across the discordance and concordance groups were
modest and often fell within the normal ranges.
However, differences in the levels of apoB were
already evident in young adulthood, and these differ-
ences were associated with the likelihood of prevalent
coronary calciﬁcation in early midlife. Therefore, these
data demonstrate that the lipoprotein phenotype of
a high concentration of cholesterol-depleted apoB
particles can precede the onset of obesity, hyper-
triglyceridemia, and hyperglycemia that, nevertheless,
could still further increase the levels of apoB when
they appear. These results conﬁrm and extend previ-
ous smaller studies that suggested that a high con-
centration of cholesterol-depleted apoB particles
may precede the onset of obesity and insulin resis-
tance (13–15). However, at 25 years of follow-up, blood
glucose and the percent of participants with diabetes
were signiﬁcantly greater in the 2 high apoB groups, as
would be expected, because of the multiple previous
reports of this association (16).
Although conventional studies comparing the pre-
dictive value of LDL-C, non–HDL-C, and apoB forclinical CVD events have produced contradictory
results (4,17,18), the results of studies using discor-
dance analysis have produced consistent results
despite the different deﬁnitions of discordance used
across studies. The LDL particle number in the
Framingham Offspring Study (19) and MESA (Multi-
Ethnic Study of Atherosclerosis) (20) has been shown
to have a greater predictive ability for CVD than LDL-C.
Similarly, apoB has been shown to have a greater
predictive ability for coronary heart disease (CHD)
events than LDL-C and non–HDL-C in the INTER-
HEART study and the Framingham Heart Study
(6,21,22). In the Women’s Health Study, non–HDL-C,
apoB, and LDL particle number demonstrated greater
predictive ability than LDL-C for CHD events (23),
although interestingly, this was not evident in the
conventional analysis of the same dataset (24). The
present study adds to this growing body of literature
by demonstrating similar results across the early
adult life course, suggesting that measuring apoB as a
marker of lipid-associated atherogenic risk may help
identify young adults at risk for midlife coronary ar-
tery disease decades before adverse levels of tradi-
tional risk factors manifest, potentially providing
opportunities for earlier intervention with lifestyle
and possibly for medication use in some individuals.
TABLE 4 ApoB, Cholesterol Levels, and Concordance/Discordance Between ApoB and Cholesterol Categories in Relation to Risk of Y25 CAC>0
OR (95% CI)
Unadjusted Model 1* Model 2* Model 3*
ApoB† tertiles
Low (referent) (n ¼ 915) 1.00 1.00 1.00 1.00
Middle (n ¼ 944) 1.77‡ (1.41–2.21) 1.62‡ (1.28–2.04) 1.58‡ (1.24–2.00) 1.53‡ (1.20–1.94)
High (n ¼ 935) 3.06‡ (2.47-3.80) 2.81‡ (2.24–3.53) 2.49‡ (1.97–3.15) 2.28‡ (1.79–2.89)
LDL-C§ tertiles
Low (referent) (n ¼ 929) 1.00 1.00 1.00 1.00
Middle (n ¼ 924) 1.51‡ (1.22–1.88) 1.45‡ (1.15–1.83) 1.47‡ (1.16–1.86) 1.41k (1.11–1.80)
High (n ¼ 941) 2.65‡ (2.15–3.27) 2.50‡ (2.00–3.12) 2.37‡ (1.88–2.99) 2.23‡ (1.77–2.82)
NHDL-C¶ tertiles
Low (referent) (n ¼ 923) 1.00 1.00 1.00 1.00
Middle (n ¼ 927) 1.62‡ (1.29–2.02) 1.52‡ (1.20–1.92) 1.47‡ (1.16–1.87) 1.40† (1.10–1.78)
High (n ¼ 944) 3.13‡ (2.53–3.88) 2.79‡ (2.23–3.50) 2.54‡ (2.01–3.22) 2.32‡ (1.83–2.95)
ApoB/LDL-C
Low/low (referent) (n ¼ 1,153) 1.00 1.00 1.00 1.00
Low/high (n ¼ 244) 1.40# (1.01–1.93) 1.30 (0.92–1.82) 1.30 (0.92–1.85) 1.29 (0.91–1.83)
High/low (n ¼ 241) 1.79‡ (1.31–2.44) 1.89‡ (1.36–2.62) 1.66k (1.18–2.33) 1.55k (1.10–2.18)
High/high (n ¼ 1,156) 2.48‡ (2.06–3.00) 2.30‡ (1.88–2.81) 2.09‡ (1.70–2.57) 1.94k (1.58–2.40)
ApoB/NHDL-C
Low/low (referent) (n ¼ 1,184) 1.00 1.00 1.00 1.00
Low/high (n ¼ 213) 1.42# (1.01–1.99) 1.30 (0.91–1.85) 1.23 (0.85–1.77) 1.19 (0.82–1.72)
High/low (n ¼ 217) 1.49# (1.06–2.08) 1.63k (1.15–2.32) 1.51# (1.05–2.17) 1.45# (1.01–2.09)
High/high (n ¼ 1,180) 2.53 (2.10–3.04) 2.32‡ (1.91–2.83) 2.07‡ (1.69–2.54) 1.91k (1.55–2.35)
*Model 1: adjusted for age, sex and race; Model 2: Model 1 þ baseline (smoking status, systolic BP, antihypertensive medication use, diabetes, and BMI); Model 3: Model 2 þ HDL-C and lipid-
lowering medication use. †Median apoB: 88 g/dl. ‡p < 0.001 compared with the referent group. §Median LDL-C: 107 mg/dl. kp < 0.01 compared with the referent group. ¶Median NHDL-C:
121 mg/dl. #p < 0.5 compared with the referent group.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Blood
concentrations of apoB, which reﬂect the total num-
ber of atherogenic lipoprotein particles, measured at
age 25 years, might be a better marker of the risk of
developing subclinical atherosclerosis by age 50 years
than either LDL-cholesterol or non–HDL-cholesterol
levels.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to determine the causes of high apoB
levels in patients with normal LDL-cholesterol and
non–HDL-cholesterol levels, and to conﬁrm associa-
tions with clinical ischemic events during long-term
follow-up.
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200STUDY LIMITATIONS. The primary strength of this
study is the quality of the CARDIA dataset. CARDIA
has used standardized data collection procedures
with rigorous quality control measures during
repeated serial examinations and measurements
over 25 years of follow-up. Nevertheless, the results
of our study should be interpreted in light of po-
tential limitations. ApoB measurements were ob-
tained at a single examination in young adulthood,
but have not been repeated. Therefore, the evolution
of apoB over time is not available. Another limita-
tion is the use of CAC, a surrogate marker of CHD
risk, as the outcome. However, strong associations
have been shown in multiple studies between CAC
and subsequent CHD events (25). However, CARDIA
does not yet have enough CHD events to generate
robust risk estimates for events.
CONCLUSIONS
These data suggest that apoB may be an important
marker of future CAD risk in young adults. Further
follow-up is warranted to determine if apoB mea-
surement in young adulthood is a marker of later CHD
event risk as well.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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